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Abstract.  We have previously shown that in some pa- 
tients with primary hyperoxaluria type 1 (PH1), dis- 
ease is associated with mistargeting  of the normally 
peroxisomal enzyme alanine/glyoxylate aminotransfer- 
ase (AGT) to mitochondria (Danpure, C. J., P. J. 
Cooper, P. J. Wise, and P. R. Jennings.  J.  Cell Biol. 
108:1345-1352).  We have synthesized, amplified, 
cloned, and sequenced AGT eDNA from a PHI pa- 
tient with mitochondrial AGT (mAGT).  This identified 
three point mutations that cause amino acid substitu- 
tions in the predicted AGT protein sequence.  Using 
PCR and allele-specific oligonucleotide hybridization, 
a range of PHI patients and controls were screened for 
these mutations.  This revealed that all eight PHI pa- 
tients with mAGT carded at least one allelewith the 
same three mutations.  Two were homozygous for this 
allele and six were heterozygous. In at least three of 
the heterozygotes, it appeared that only the mutant al- 
lele was expressed.  All three mutations were absent 
from PH1 patients lacking mAGT.  One mutation en- 
coding a Gly~Arg substitution at residue 170 was not 
found in any of the control individuals.  However, the 
other two mutations,  encoding Pro~Leu and Ile~Met 
substitutions at residues  11 and 340, respectively, 
cosegregated in the normal population at an allelic fre- 
quency of 5-10%.  In an individual homozygous for 
this allele (substitutions at residues 11 and 340) only a 
small proportion of AGT appeared to be rerouted to 
mitochondria.  It is suggested that the substitution at 
residue  11 generates an amphiphilic  alpha-helix  with 
characteristics  similar to recognized mitochondrial tar- 
geting sequences, the full functional expression of 
which is dependent upon coexpression of the substitu- 
tion at residue 170,  which may induce defective perox- 
isomal import. 
p 
RIMARY hyperoxaluria type 1 (PH1)  t is a lethal auto- 
somal recessive disease caused by a deficiency of the 
liver-specific peroxisomal enzyme alanine/glyoxylate 
aminotransferase  1 (AGT, EC 2.6.1.44)  (Danpure and Jen- 
nings,  1986). Whereas most PHI patients  have a complete 
deficiency of AGT enzyme activity (Danpure and Jennings, 
1988) and AGT immunoreactive  protein (Wise et al., 1987), 
about one-third possess significant amounts of residual AGT 
activity and protein.  In all of these latter patients so far exam- 
ined it appears that the disease is due, at least in part, to a 
unique protein targeting defect in which AGT is erroneously 
routed to the mitochondrion instead of its normal intracellu- 
lar location, the peroxisome (Danpure et al.,  1989, 1990). 
The  subcellular distribution  of hepatic AGT is  species 
specific. In cat and dog AGT is mitochondrial,  whereas in 
1. Abbreviations used in this paper: AGT, alanine/glyoxylate aminotransfer- 
ase  [; ASO, allele-specific oligonucleotide;  mAGT, mitochondrial  AGT; 
MTS, mitochondrial  targeting sequence; pAGT, peroxisomal AGT; PCR, 
polymerase chain reaction; PH1, primary hyperoxaluria type 1; PTS, perox- 
isomal targeting  sequence. 
rabbit,  guinea  pig,  macaque,  and  human  the  enzyme is 
confined  to the peroxisome (Noguchi and  Takada,  1979; 
Takada and Noguchi, 1982a,b; Okuno et al., 1979). In con- 
trast, rat, mouse, and hamster have significant levels of AGT 
present in both peroxisomes and mitochondria (Noguchi et 
al.,  1979; Takada and Noguchi, 1982a,b). In an attempt to 
explain the molecular basis of the rerouting phenomenon in 
PHI patients with mitochondrial AGT (mAGT), we recently 
determined the nucleotide sequence of normal human perox- 
isomal AGT (pAGT) eDNA (Takada et ai., 1990), and com- 
pared this with the published eDNA sequence encoding rat 
mAGT  (Oda et al.,  1987).  This  revealed  that  the human 
eDNA has a sequence identity with its counterpart in the rat 
of 74 % within  the region encoding the rat amino-terminal 
mitochondrial targeting  sequence (MTS), but that this MTS 
is not expressed as part of the human protein due to a coding 
difference at the site corresponding to the rat protein transla- 
tion start site (ATG in the rat gene, ATA in the human gene). 
This provided an explanation for the exclusive peroxisomal 
localization of AGT in humanliver. In addition,  the high se- 
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compared  to  79%  between  the  shared  coding  regions) 
opened up the possibility that mutations which extend the 
open reading frame of the human gene to include additional 
amino-terminal sequences corresponding to partial or com- 
plete versions of the rat MTS might be a factor in the rerout- 
ing of AGT in PHI. 
In the present study we have determined the AGT eDNA 
sequence  of  a  PHI  patient  with  mAGT,  and  screened 
genomic DNA from a range of PHI and normal individuals 
for the differences observed between this sequence and that 
of normal human AGT eDNA. We discuss the possible role 
of these mutations in the rerouting of AGT to  the mito- 
chondria. 
Materials and Methods 
Isolation of  poly-A  ÷  RNA 
Total  RNA  was  isolated  from  liver  stored  in  liquid  nitrogen  by  the 
guanidinium isothiocyanate/caesium  chloride method  (Chirgwin et  al., 
1979), and poly A + mRNA was selected by oligo dT-cellulose (Boehringer 
Mannheim UK, Lewes, East Sussex,  UK) column chromatography (Aviv 
and Leder,  1972). 
Synthesis, Polymerase Chain Reaction Amplification, 
and Cloning of  cDNA 
For eDNA synthesis,  2/tg of poly-A  + RNA was heated to 90oC for 5 rain, 
chilled on ice, and incubated with 500 U of M-MLV reverse transcriptase 
(Gibco BRL, Paisley, Scotland,  UK) and 50 pmol of primer in a total vol- 
ume of 25/zl of reverse transcription buffer (50 mM Tris-HCl, pH 8.3, 75 
mM KCI,  10 mM DTT, 3 mM MgC12, 100/tg/ml BSA,  1 U//~I placental 
ribonuclease inhibitor (Boehringer Mannheim UK, Lewes,  East Sussex, 
UK) for 10 rain at room temperature, and then for 90 rain at 42°C.  Total 
reverse transcription reactions (25/tl) were added to 75/zl of polymerase 
chain reaction (PCR) buffer (10 mM Tris-HCl, pH 8.3, 50 mM KCI,  1.5 
mM MgCI2, 0.01% [wt/vol] gelatin) containing an additional  50 pmol of 
the reverse  transcription primer and 100 pmol of a second PCR primer. 
Cloned Taq Folymerase  (2.5 U) (Amplitaq; Perkin Elmer Corp., Norwalk, 
CT) was added, and the reactions were thermally cycled (94°C  for 90 s, 
55°C for 90 s, 72°C for 60 s, for 35 cycles, and then 72°C for 10 rain) under 
mineral oil. PCR products were identified by agarose gel electrophoresis 
and Southern blotting, gel purified, and cloned into pUC19. The sequences 
of the primers for reverse transcription/PCR are given in the Oligonucleo- 
tide subsection. 
Purification and Sequencing of  Plasmid DNA 
Plasmid DNA was prepared by the alkaline/SDS  lysis method (Maniatis et 
al.,  1982) from 5 ml of log-phase culture, and sequenced  using modified 
T7 DNA Polymerase (scquenase; United States Biochemical Corporation, 
Cleveland, Ohio). In some instances plasmid DNA from 250-ml cultures 
was purified on caesium chloride gradients before sequencing. E. coli strain 
JM101 was used throughout. 
Isolation and Characterization of a Genomic Clone 
Encoding AGT 
Approximately 1  x  106 plaque forming units of a library of 10-20 kbp 
San3A partial digestion products of human DNA, cloned into the vector 
lambda 47.1 (Loenen and Brammar, 1980) were screened by plaque hybrid- 
ization (Benton and Davis,  1977). The probe was full-length normal AGT 
eDNA, labeled by random priming (Feinberg and Vogelstein, 1984). A sin- 
gle hybridization  positive was plaque purified, and DNA was prepared from 
plate lysates  of this clone (L-AGTI) (Helms et al.,  1985) and restriction 
mapped. Regions  of this done with homology tO specific  regions  of the 
eDNA were subcloned into pUC19 and sequenced. 
Isolation and PCR Amplification of  Blood 
Genomic DNA 
High molecular weight genomic DNA was isola~d from whole blood by 
standard techniques.  1-/~g  aliquots of purified DNA were heated at 95°C for 
5 rain before addition to the PCR reaction (100/zl). PCR conditions were 
as described above. The sequences of the PCR primers are given in the Oli- 
gonucleotide  subsection. 
Allele-specific Oligonucleotide  Hybridization 
PCR product (5 #l/spot) was denatured in 0.3 M  NaOH,  neutralized  in 
0.3 M Tris-HC1, pH 7.4/0.75 M NaCI,  spotted onto nylon membrane (Hy- 
bond-N; Amersham International plc,  Amersham, Bucks., UK) and UV- 
fixed. Oligonucleotide  probes (20 pmol) were end-labeled  (Maniatis et al., 
1982) and purified  on Nensorb columns (DuPont  UK, Stevenage,  Hem., 
UK).  Prehybridization (>4 h) and hybridization (>16 h) were at 37°C  in 
0.1% (wt/vol) SDS, 0.2% (wt/vol) BSA, 0.2% (wt/vol) Ficoll, 0.2% (wt/vol) 
polyvinyl pyrrolidone,  100/~g/ml boiled, sonicated  herring sperm DNA, 
and 6×  SSC (1×  SSC  =  0.15 M NaCI,  15 mM sodium  citrate,  pH 7.0). 
The filters were washed at 37°C in 6x SSC, 0.1% (wt/vol) SDS (15 rain, 
twice), then in 3 M tetramethylammonium chloride, 50 mM Tris-HC1, pH 
8.0, 2 mM EDTA, 0.1% (wt/vol) SDS (3 ×  15 rain, once at 37°C, then twice 
at 47°C) (Wood et al.,  1981). 
Oligonucleotides 
All oligonucleotides were synthesized using a Milligen/Biosearch 7500 DNA 
synthesizer (Millipore (UK) Ltd., Watford,  Hertfordshire, UK).  Oligonu- 
cleotides used as allele-specific  probes are described in the legend to Fig. 
5. For amplification  of eDNA by reverse transcription/PCR three pairs of 
primers (PA/PB, PC/PD, PE/PF) were used. PA, PC, and PE were antisense 
(reverse transcription) primers. PB, PD, and PF were the respective primers 
for synthesis of second strand eDNA. The sequences of these primers were 
as follows,  with the corresponding positions relative  to fuU-length AGT 
eDNA shown in parentheses. PA, 5'-TCCAIUATCTGGTACATATC-3' (nu- 
cleotides 295-276); PB, 5'-CACCAATCCI~_ACCTC~AC-3'  (14-33); PC, 
5'-TTAAGAACAGCAGCACTGCd2-3'  (582-563); PD, 5'-AACCTGCCTC- 
CTCGCATCAT-3'  (216-235);  PE,  5"GGACC~TCTGTTT-3' 
(1,389-1,370);  PF,  5'-GATATGTACCAGA'[CATCrGA-3'  (276-295).  PCR 
primers for amplification  from genomic DNA were based upon sequences 
from the AGT genomic clone, the full structure of which will be published 
elsewhere (Purdue, P. E., M. Lumb, M. Fox, (3. Griffo, C. Hamon-Benais, 
S. Povey, and C. J. Danpure,  manuscript submitted for publication).  The 
sequences of the three pairs of primers (PB/PG, PH/PI, PJ/PK) are as fol- 
lows.  PB,  see above; laG, 5'-ATCTGTC~.d3~CATC,-G-3';  PH,  5'- 
C,-CCAGTC~TGCTGT'I~TTAA-3';  PI,  5'-TCTGAGCTGAGCTCCAGTC- 
C-3'; PJ, 5'-T'ICCCACAGTCACCACTGTG-3'; PK, 5'-CCTGG~CAG- 
TCCTGCTC-Y. 
Results 
cDNA Sequence Analysis 
Three overlapping regions of eDNA covering nucleotides 
34-1,369  (relative to the 5' end of the full-length eDNA; 
Takada et al.,  1990),  were synthesized from poly A + RNA 
extracted from the liver of a Pill patient with mAGT  (patient 
A), and amplified by PCR (Fig. 1 a). These eDNA products 
were cloned and sequenced, revealing a total of five differ- 
ences to the normal eDNA sequence. (Throughout this paper 
XnY is used to denote an X to Y mutation at nucleotide n 
relative to the 5' end of full-length AGT eDNA.)  One of 
these, T937A, was identified as being an artefact of the PCR 
process by the following criteria. First, this change was only 
present in a single clone out of three sequenced in this re- 
gion, despite evidence (discussed later) that all the AGT 
mRNA derives from a single allele in this patient, and sec- 
ondly, the loss of a  site for the restriction enzyme Dde I 
predicted by this mutation could not be detected when total 
PCR product was digested by this enzyme and analyzed by 
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1 ~t.SHKLLVTPLKALLKPLSIPNQLLLGPGPSNLPPRIMAAGGLQMIGSMSKDMYQIMDRI  60 
P 
6,  KEGIQYVFQTRNPLTLVISGSGHCALEAALVNVLEPGDSFLVGANGIWGQRAVDIGERIG  ,20 
121  ARVHpMTKDPGGHYTLQEVEEGLAQHKPVLLFLTHGESSTGVLQPLDGFRELC~YKCLL  180 
G 
181  LVDSVASLGGTPLYMDRQGIDILYSGSQKALNAPPGTSLISFSDKAI~SRKTKYFSF  240 
241 YLDIKWLANFWGCDDQpRMYI~ITIPVlSLYSLRESLALIAEQGLENSWRQHREAAAYLHG  300 
301  RLQALGLQLFVKDPTLRLPTVTTVAVPAGYDWRDIVSYVMDHFDIEIMGGLGPSTGKVLR  360 
I 
361  IGLLGCNATR~rVDRVTF,  ALRk6LQHCPKKKL 392 
Figure 1. Analysis of AGT eDNA from a patient with mAGT (pa- 
tient A). (a) eDNA (nucleotides 34-1,369, excluding primers) was 
synthesized in three overlapping segments which are shown as filled 
bars aligned with a representation of full-length AGT eDNA (open 
bar, with the coding region hatched). Numbers are base pairs rela- 
tive to the 5' end of the full-length eDNA (Takada et al., 1990) and 
correspond to the 3' ends of the PCR primers. The positions of the 
identified mutations  are shown with  arrows. (b) The predicted 
amino acid changes resulting from the mutations at positions 154, 
630, and 1,142. Amino acid residues are numbered relative to the 
amino-terminal methionine. (c) The derived amino acid sequence 
of AGT from patient A. The positions of the differences to the nor- 
mal sequence are shown in bold, with the corresponding amino acid 
in the normal  sequence shown below. These sequence data are 
available from EMBL/G-enBank/DDBJ under accession number 
X53414. 
agarose gel electrophoresis (not shown). The remaining four 
observed differences were interpreted as being genuine mu- 
tations, being present in every clone (minimum three) se- 
quenced.  Of these four point mutations,  one (C386T) is in 
the wobble position of an alanine codon, but the other three 
result in alterations  in the predicted protein sequence,  as 
shown in Fig.  1, b and c. 
Isolation and Characterization era Genomic Clone 
Encoding AGT 
For the majority of individuals, both with PHI and controls, 
whom we wished to screen for the identified mutations, it 
was not possible to synthesize eDNA due to the nonavailabil- 
ity of suitable liver tissue. As a prerequisite to direct analysis 
of AGT sequences within genomie DNA isolated from the 
blood of these individuals, a genomie clone encoding normal 
human AGT was isolated and partially characterized. A par- 
tial restriction map of this clone is shown in Fig. 2. Regions 
of the clone that correspond to the mutant sites within the 
eDNA  were identified by Southern blotting  (not  shown). 
These were a 1.42-kbp Sph I-Sph I fragment with homology 
to a probe covering nueleotides 1-250 of the eDNA, a 2.0- 
kbp  Sph  I-Bam HI  fragment with  homology to  a  probe 
covering nucleotides 535-615 of the eDNA, and a 0.9-kbp 
Pst I-Pst I fragment that hybridized to a probe of nucleotides 
1,050-1,270 of the eDNA. These fragments were cloned into 
pUC19 and sequenced. As  shown in Fig.  2,  in each case 
these clones span the entire exon carrying the mutant site. 
Clone pAX covers the first exon (eDNA nueleotides 1-287) 
together with '~1.0 kbp of 5' nontranscribed DNA and 135 
bp of the first intron. Clone pAY includes an exon of 101 bp 
(eDNA nudeotides 546-646) and flanking intron sequences, 
and clone pAZ includes an exon of 129 bp (eDNA nucleo- 
tides 1,065-1,193)  with flanking intron sequence and part of 
the next exon. Using PCR primers based on the sequences 
of these clones, products of 328, 126, and 193 bp, which in- 
clude the sites of mutations C,~T, G630A, and A]I42G, respec- 
tively, were amplified from DNA extracted from the blood 
of  individuals A-L and a number of  controls whose subcellu- 
lar distribution of AGT is unknown. 
The C,.T Mutation Is a Common Feature of PH1 
Patients with mAGT 
Of the three mutations identified in the cDNA of patient A, 
S  S B  S  B  R  B  P  P  Figure 2. Partial physical map 
of genomie clone L-AGTI. (a) 
a  11 kbPl  The filled boxes represent re- 
gions that hybridized to probes 
/"  "'-,  ',  corresponding to specific re- 
,  ,  gions of AGT eDNA,  as de-  /  -.  k  ,-  -  ,  scribed in the text. These frag- 
"  pAX  pAY  ""  ,  .,  pAZ  ',  ments  were  subeloned  into 
/  ""  '  pUC19 to produce clones  pAX, 
b  [  /~.}  z~Jx  ]  J[~]  ~,  lkbp  ,  pAY, and pAZ.  P,  Pst I;  B, 
\  Barn HI; S, Sph I; R, Eco RI. 
1  l  287  546t646  106511193  (b)  The  structure  ofclones 
C154T  G630A  Al142  G  pAX' PAY' and lX~Z  as deduced 
from their  sequences. Exons 
are represented with hatched boxes and introns with open boxes. The numbers represent the positions of  the eDNA sequence corresponding 
to the intron/exon boundaries. The mutation sites are marked with arrows. 
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patients. (a) Sty I sites within exon 1 PCR product. The CloT mu- 
tation destroys a site for the restriction enzyme Sty I (CCAAGG 
mutated to TCAAGG). Whereas normal exon 1 PCR product (328 
bp) will give Sty I digestion products of 47, 60, 35, and 186 bp, the 
PCR product from a C154T mutant allele will digest to products of 
47, 60, and 221 bp. Sty I sites are marked with arrows, with the 
polymorphic site indicated by the broad arrowhead. (b) Ethidium 
bromide stained 2% agarose gel of Sty I digestion products from 
PHI patients (A-K) and controls (L, N22). The sizes are in base 
pairs. The molecular weight markers were the 1-kbp  ladder (Gibco 
BRL, Paisley, Scotland, UK). The reason for the lower intensity 
of the 186-bp band relative to the 221-bp band in patients A-F is 
unclear, but is possibly due to formation of heteroduplexes, which 
would not be cleavable at the polymorphie site, during the later 
stages of the PCR. 
trophoresis (Fig. 3 b). While the two controls and the three 
PHI patients without mAGT gave a digestion product of 186 
bp (but no product of  221 bp), suggesting that these individu- 
als are homozygous for the normal allele, the digestion prod- 
uets from all eight PHI patients with mAGT include a frag- 
ment of 221 bp, implying the presence of an allele carrying 
the  CloT  mutation.  Patients  A-F,  whose AGT  activities 
range from 0-12.9% of normal (Table I), appear to be het- 
erozygous for the mutation, in that they also have a  186-bp 
digestion product, while patients G and H, whose AGT ac- 
tivities are 27.1 and 28.7 % of normal, respectively (Table I), 
have no 186-bp product, implying that they are homozygous 
for the C~T mutation. 
Three Patients Heterozygous for the CI~T Mutation 
Express Only the Mutant Allele 
Liver tissue suitable for extraction of intact RNA was avail- 
able from three (A-C) of the six patients heterozygous for 
the C~54T mutation, mRNA was prepared from these livers 
and from the liver of patient K (normal level of pAGT pro- 
tein, but a complete deficiency of AGT enzyme activity) and 
a normal control CK, AGT distribution unknown), and eDNA 
encoding  nueleotides  14-295  (including  flanking  primer- 
derived sequence) was synthesized and amplified as described 
earlier. As for the PCR products from genomie DNA, the 
C~54T mutation is detectable by virtue of the Sty I polymor- 
phism, giving a Sty I digestion product of 175 bp from PeR 
product derived from mutant eDNA, compared to 140 bp for 
the normal eDNA (Fig. 4 a). The Sty I digests of the PCR 
product from patients A, B, C, K and the normal control (X) 
were fraetionated by agarose gel electrophoresis, Southern 
Table L Description of  Patients 
the C154T mutation seemed the most likely to have a direct 
causal role in the generation of a MTS, for the following rea-  Patient 
sons. First, it is to be expected that the signals responsible 
for targeting of the mutant AGT to the mitochondria will, 
in common with the MTSs of the vast majority of imported  A 
mitochondrial  proteins,  be  expressed  as  an  amphiphilie  B 
amino-terminal domain  (Sehatz,  1987;  Roise and  Sehatz,  c 
D  1988).  Whereas  it is  not  easy to  envisage  the  Gt~  or 
AH42G  mutations directly  affecting  the  amino-terminal  E  F 
structure of AGT, it seems entirely possible that the proline  G 
to leucine conversion at residue 11 caused by the C~5,T mu-  H 
tation could induce significant structural alterations in this  I 
region. Secondly, the amino-terminal sequence of AGT dis-  j 
plays a number of the features common to MTSs (e.g., high  K 
in basic amino acids, no acidic amino acids), supporting the  L 
argument that structural alterations in this region could re-  M 
suit in formation of  a peptide domain with mitoehondrial tar- 
geting ability. 
For these reasons individuals A-L were initially screened 
for this mutation. As shown in Fig. 3 a, the C~T mutation 
destroys a site for the restriction enzyme Sty I, resulting in 
the generation of a novel 221-bp Sty I-Sty I restriction frag- 
ment.  In the absence of the C,54T mutation, this region is 
digested to products of 186 and 35 bp. First exon PCR prod- 
uct from PHI patients A-K and two controls (L,N22) were 
digested with Sty I  and fraetionated by agarose gel elec- 
Mutations 
AGT  CRM  Subcell  CI54T  G~A  An42G 
% 
8.7  +  M  C/T  G/A  A/G 
8.2  +  M  C/T  G/A  A/G 
5.6  +  M  C/T  G/A  A/G 
12.9  +  M  C/T  G/A  A/G 
7.8  +  M  C/T  G/A  A/G 
0.0  +  M  C/T  G/A  A/G 
27.1  + +  M  T/T  A/A  G/G 
28.7  + +  M  T/T  A/A  G/G 
0.0  -  -  C/C  G/G  A/A 
0.7  -  -  C/C  G/G  A/A 
1.8  ++ +  P  C/C  G/G  A/A 
106.2  + + +  P  C/C  G/G  A/A 
92.1  + + +  P/M  T/T  G/G  G/G 
Patients A-K have PH1, whereas patients L and M have idiopathic  oxalosis of 
unknown etiology (possibly secondary to renal failure in L and oxalate hyper- 
absorption in M). AGT, enzyme activity, corrected for crossover from gluta- 
mate/glyoxylate aminotransferase, expressed as percent of mean control level 
(Danpure and Jennings, 1988). CRM, estimated level of immunorea~ive  AGT 
protein (+ + +, normal; + +, intermediate; +, low;  -,  undetecmble) as de- 
termined by irmnunoblotting (Wise et al., 1987).  Subcell, subeellular distribu- 
tion of immunoreactive AGT protein  (M,  >  90%  mitochondrial, P,  100% 
peroxJsomal, P/M, ,,,90% peroxisomal, '~10% mitochondrial) as determined 
by immunoelectron microscopy (Cooper et al., 1988). Mutations, sequence at 
the mutant sites identified  in this study. CloT, G~3oA,  and Au42G are the three 
mutations for which the patients were screened. A,  C,  G, and T, the bases 
present in each allele at the mutant site. 
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four PH1 patients. (a) Sty I sites within the normal and CIssT mu- 
tant AGT eDNA (nucleotides 14-295). Normal eDNA gives re- 
striction digestion products of 47, 60, 35, and 140 bp, and the mu- 
tant eDNA gives products of 47, 60, and 175 bp. Sty I sites are 
marked with arrows, with the polyrnorphic site indicated by the 
broad arrowhead. (b) Southern blot of AGT eDNA (nucleotides 
14-295, including 20 bp of primer sequence at either end), from 
four PH1 patients (,4, B,  C, K) and a control (X), fractionated 
through a 2% agarose gel before (-) and after (+) Sty I digestion. 
The probe was normal AGT eDNA (nucleotides 14-295). Patients 
A-Chave mAGT,  patient/(has pAGT  immunoreactive  protein, and 
control X has unknown AGT distribution. 
blotted,  and probed with AGT  eDNA.  This blot  (Fig.  4 b) 
revealed  that,  whereas patient  K and  the  normal control  gave 
a single  band at 140 bp, the patients  hetcrozygous for this 
mutation (A-C) gave a single  band of 175 bp. This implies 
that  all  the  eDNA  synthesized  in  patients  A-C contains  the 
CI~T mutation, which in  turn suggests that the only allele 
expressed in the livers of these patients is the mutant one. 
In the case of  patient A this is consistent with the finding that 
all eDNA clones sequenced contained the C~sT, C~T, GsoA, 
and AH,2G mutations. 
The C~,T Mutation Is Not Restricted to PHI Patients 
To verify that the loss of the Sty I site in all eight patients 
with mAGT is due to the same mutation, the first exon PCR 
product from patients A-L was screened by hybridization to 
allele-specific oligonucleotides (ASOs) corresponding to the 
normal and patient A AGT eDNA sequences around nucleo- 
tide 154. The results, shown in Fig. 5 b, confirm that all the 
patients with mAGT do carry the C~sT mutation, whereas 
patients I-L do not. Our use of this technique was extended 
to screen first exon PCR product from a range of controls, 
and a sample of the results is also shown in Fig. 5 b. This 
revealed that the C~sT mutation is present at an allelic fre- 
quency of 5-10% in the normal population. Of 60 individu- 
als screened, 52 were homozygous for the normal allele, 7 
were heterozygous for the C~T mutation, and 1 was homo- 
zygous for the mutation. While this clearly implies that the 
C~T mutation is insufficient to cause PH1, it does not ne- 
cessarily indicate that this mutation is not causally related 
to  AGT rerouting,  since it has not been established that 
rerouting per se is sufficient  to cause disease, and the subcel- 
lular distribution of AGT in the controls is unknown. 
The G~4 Mutation Is Restricted to PHI Patients 
with mAGT 
The high allelic frequency of the Clot mutation in the nor- 
mal population suggested that the other mutations observed 
in the eDNA of patient A may be necessary for the onset of 
disease in patients with mAGT. These mutations, G6~, and 
AH,2G, cause a  glyeine to  arginine conversion at residue 
170 and an isoleucine to methionine conversion at residue 
340, respectively. The distribution of  these mutations among 
the PH1  patients and a  subset of the controls previously 
characterized  for  the  C~T  mutation was  established by 
screening appropriate PCR products with allele-specific oli- 
gonucleotide probes corresponding to the respective normal 
and mutant sequences (Fig. 5, c and d). This revealed that 
for all the PH1 patients in this study (A-K) the paRerns of 
distribution of the G~oA and AH,2G mutations are identical 
to that of the C~sT mutation. Patients G and H are homo- 
zygous for all three mutations, whereas patients A-F are het- 
erozygous for each,mutation, and patients I-K (as well as L) 
are homozygous for the normal sequence at all three sites. 
The linkage between the Crest and A~14~G mutations extends 
to the normal individuals included in this study. In 41 of 42 
such control subjects (including one homozygous and seven 
heterozygous for the C~sT mutation) the pattern of occur- 
rence of the A~14zG  mutation matched that of the CIsT mu- 
tation. The exception was an individual (N~) homozygous 
for the normal sequence at position 154,  but heterozygous 
for the A11,~G mutation. In contrast, the G~oA mutation is 
completely absent from these 42 normal individuals (Fig. 5 
c).  The implication of this is that whereas the combined 
effects of the C]sT and AH~2G  mutations are insufficient to 
cause PH1, even when present on both alleles, the additional 
presence of the G~A mutation is of significant importance 
in  the  determination of  disease  state  in PHI patients  A-H. 
This suggests  a role  for  the  G~A  mutation in  AGT  rerout- 
ing. However, since  the subccllular  distribution  of  AGT  in 
the  normal controls  is  unknown due  to  the  nonavallability  of 
liver  biopsies,  and since  it  has not  been established  whether 
AGT rerouting  per se  is  sufficient  to  cause disease,  this  data 
does not rule  out the possibility  that  the role  of  the G6~ 
mutation in  the  onset  of  disease  is  not  directly  related  to  AGT 
rerouting. 
The G~  Mutation Is Important for AGT Rerouting 
Towards the completion of this study a patient with primary 
hyperoxaluria of unknown etiology (possibly oxalate hyper- 
absorption) was brought to our attention. In this individual 
PH1 was excluded on the basis of  normal hepatic AGT activ- 
ity (Table I, patient M). ASO screening of the AGT gene in 
this patient revealed that she was homozygous for the mutant 
allele carrying the C,~T and An,2G mutations, but lacked 
the Gs0A mutation (Fig. 6 b). To investigate the subcellular 
distribution of AGT in this individual immunoelectron mi- 
Purdue et al. Peroxisome-to-Mttochondrion Enzyme Rerouting  2345 Figure 5.  Dot blots of PCR product probed with ASO. (a) Grid showing the source of the PCR product corresponding to each position 
on the dot blots. Pn, cloned AGT cDNA (normal). Pro, cloned AGT cDNA (patient A). A-L are the patients in Table I. NI-N~ are con- 
trois.  (b)  The  Clot  mutation. The probes  cover nucleotides  147-161  of the  cDNA  sequence.  (c)  The  G63oA mutation (nucleotides 
623-637). (d) The AI~42G  mutation (nucleotides 1,135-1,149). The sequences of the probes were as follows. 154C =  5'-ACCCCCCCC- 
AAGC~C-3';  154"£ =  5'-ACCCCCCI~.AAGCK~C-3'; 630G  =  5'-TGGCTTCGCK~GAACT-3'; 630A  --  Y-TGGCTTCAGGGAACT-3'; 
1142,4 =  5"AC  GTCATAC~C  CACT-  3'; 1142  G =  5"  ACGTCA~CCACT-  3'; In each case the oligonucleotide  probes are 15mers, differing 
only at the central residue. The generation of the PCR product for the blots in b, c, and d  is described in the text. 
The Journal of Cell Biology, Volume 111, 1990  2346 Figure 6. Comparison of  the patterns  of subcellular  AGT distribution  in three patients with different AGT alleles. (a) Protein-A gold Immu- 
noelectron microscopy. --.~, peroxisomes; m~,, mitochondria. L, M, and H, patients  (see Table I for the patient details  and Danpure 
et al.  [1989] for the method) (b) ASO hybridizations.  The PCR products and probes are described in the text and the legend to Fig.  5. 
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Figure 7. Predicted structural properties of the amino-terminal re- 
gion of normal and mutant  AGT. (a)  Helical wheel analysis. 
Residues 1-18 of normal AGT are plotted as described by Schitfer 
and Edrnundson  (1967). Positively  charged residues are circled and 
hydrophobic residues underlined. The arrow shows the proline to 
leucine substitution caused by the C~s4T mutation. (b) Predicted 
secondary structure. The alpha helix forming potential of residues 
1-18 of normal AGT are plotted according to Chou and Fasman 
(1974). The bold bar at residue 11 shows  the alteration in predicted 
structure caused by mutation C~54T. 
croscopy was performed on a liver biopsy (Fig. 6 a). This 
revealed that although the majority (>90%) of immunoreac- 
tive AGT protein was peroxisomal, a small (<10%) but sig- 
nificant proportion of the protein was located in the mito- 
chondrion. This contrasts with the situations in controls, 
where there is no detectable mitochondrial labeling and PHI 
variants with mAGT, where >90 % of immunoreactive AGT 
is mitochondrial (Fig. 6 a). A possible explanation of this 
pattern of distribution is that the appearance of mAGT and 
loss of pAGT in patients A-H are caused by two distinct but 
related events.  Generation of the MTS, which is dependent 
upon the C~T and/or AH42G mutations, but not the Gt~A 
mutation, will lead to diversion of  a small proportion Of  AGT 
protein to the mitochondrion, presumably through genera- 
tion of a weak MTS. However,  the Gt~  mutation, possi- 
bly through interference with the peroxisomal targeting and/ 
or retention of AGT, is also required to achieve the pattern 
of AGT distribution observed in patients A-H (i.e., 90% of 
AGT within the mitochondria). 
Discussion 
Mutations in the AGT Gene of Patients with mAGT 
The results presented in this paper show that the targeting 
of AGT to the mitochondrion instead of the peroxisome, 
which is, at least in part, responsible for disease in up to one- 
third of  patients with PHI, is closely correlated with the pres- 
ence  and expression  of an  allele  encoding AGT  protein 
which differs from the normal protein at three positions, in 
each  case by a  single residue.  The mutations Cts,T and 
A~,2G, which cause a proline to leucine substitution at resi- 
due 11 and an isoleucine to methionine substitution at resi- 
due 340,  respectively, appear  to cosegregate as an allele 
which is not only common to all PH1 patients with mAGT, 
but also present in the normal population at an allelic fre- 
quency of 5-10%. Such a high aUelic frequency implies that 
as much as 1% of the population could be homozygous for 
these two mutations. Given that the incidence of PH1 is esti- 
mated to be very low, probably <0.002 % of live births, this 
strongly suggests that expression of an  allele(s)  carrying 
these two mutations is insufficient to fully account for dis- 
ease in PH1 patients with mAGT. 
The third mutation, G~,oA, which causes a glycine to ar- 
ginine conversion at residue  170, appears  to postdate the 
C~s4T and A~42G mutations, having originaily arisen within 
an aUele carrying these latter two mutations. The resultant 
allele, with the Gt~A mutation flanked by Ct~T and A,42G, 
is common to all PH1 patients with mAGT, but absent from 
all the PH1 patients without mAGT and 42 control subjects 
(whose subcellular distribution of AGT is unknown, but is 
presumed to be mostly or entirely peroxisomal) included in 
this study. While this clearly implicates Gt~  as being im- 
portant in the development of disease in PHI patients with 
mAGT, it is not yet clear whether this mutation alone is 
sufficient to cause disease, or whether C~5,T and/or Am2G 
are also necessary. 
Implications for AGT Targeting 
Of the three mutations, Ct54T appears to be the most likely 
to be directly causally related to the generation of a MTS. 
The proline to leucine conversion caused by this mutation 
lies within the amino-terminal region of the protein where, 
by analogy with the vast majority of MTSs (Schatz, 1987), 
the MTS of the mutant AGT might be expected to reside. In 
addition, the amino acid sequence of AGT in this region dis- 
plays the salient features shared by almost all amino-terminal 
MTSs, namely an absence of acidic amino acids but a high 
proportion of basic amino acids, distributed such that the 
structure of the signal peptide, which is thought to be alpha- 
helical in most cases, is markedly amphiphilic (Roise and 
Schatz, 1988; von Heijne, 1986; Lemire et al., 1989). When 
the first 18 amino acids of normal AGT are subjected to heli- 
cal  wheel analysis (Fig.  7  a)  (Schiffer and  Edmundson, 
1967), the structure shows clear amphiphilicity. That this se- 
quence does not act as a MTS is likely to be due largely to 
the proline-proline doublet at residues 10-11. Whereas the 
sequences either side of these prolines would be predicted 
to favor an alpha-helical conformation (Fig. 7 b) (Chou and 
Fasman, 1974), the helix destabilizing effect of two adjacent 
prolines virtually abolishes any possibility of this region of 
AGT existing as a continuous alpha-helical domain. Indeed, 
of 37 pro-pro doublets in proteins of determined structure, 
none exist in the central portion of an alpha-helix (MacAr- 
thur, M. W., and J. M. Thornton, personal communication). 
The predicted structural properties of this region of the mutant 
protein, with proline replaced by leucine at residue 11, are 
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alpha-helix, but in this case it seems much more likely that 
such a structure might exist. Single proline residues do oc- 
casionally exist within alpha helices when they are flanked 
by sequences that favor such a conformation (Barlow and 
Thornton, 1988).  The only significant effect of single pro- 
lines in helices is the introduction of a kink of '~ 26 degrees 
(Barlow and Thornton, 1988),  which would be insufficient 
to disrupt the amphiphilicity of  the putative alpha helix at the 
amino terminus of mutant AGT. This is consistent with the 
results of a recent investigation by Lemire et al.  (1989) in 
which the predicted helical amphiphilicity of a range of pep- 
tides  encoded by random  sequence  oligonucleotides was 
compared to the functional mitochondrial targeting ability of 
these peptides. This comparison revealed an overall correla- 
tion between predicted helical amphiphilicity and functional 
mitochondrial targeting ability. However, peptides predicted 
to have significant helical amphiphilicity which also con- 
tained multiple helix-breaking residues were generally to- 
tally inactive as MTSs. This is highlighted by the observation 
that of the 80 peptides analyzed by these workers, none of 
the 60 sequences with mitochondrial targeting ability in- 
eluded Pro-Pro doublets, whereas 2 of the 20 nonfunctional 
peptides did. In contrast, 16 of the 60 functional peptides in- 
cluded a single proline, and 1 included 2 nonadjacent pro- 
lines, suggesting that single prolines can be accommodated 
within amphiphilic alpha-helical MTSs. 
Although the mutation at residue 11 can be envisaged as 
being causally related to the generation of  an amino-terminal 
MTS in AGT, it is not clear whether such an event would be 
sufficient not only to result in targeting to the mitochon- 
drion, but also to abolish targeting to the peroxisome. The 
levels of residual peroxisomal AGT in PH1  patients with 
rerouted enzyme is very low (0.3-3% normal) (Danpure et 
al., 1989; unpublished observations), implying that the abil- 
ity to accumulate AGT in peroxisomes is severely impaired 
in these individuals. Whether this loss of  peroxisomal target- 
ing activity is an unavoidable consequence of acquisition of 
a functional MTS, or alternatively whether it is a prerequi- 
site for the accumulation of significant levels of AGT in the 
mitochondrion is not known. 
There are two possible ways in which generation of an 
amino-terminal  MTS  could  affect peroxisomal  targeting. 
One possibility is that the same mutation which generates the 
MTS  also  destroys  the  peroxisomal  targeting  sequence 
(PTS).  Although the molecular basis of targeting of AGT to 
the peroxisome is not known, this seems unlikely in view of 
the increasing evidence in favor of carboxy-terminal PTSs 
(Gould et al.,  1987, 1988, 1989, 1990;  Miyazawa et al., 
1989).  The extreme carboxy-terminal sequence of AGT, as 
deduced from the eDNA sequence (-KKKL) shows similari- 
ties to the carboxy-terminal sequence of firefly luciferase 
(-KSKL), the last three amino acids of which have been 
shown to be a necessary and sufficient PTS (Gould et al., 
1989).  Whether this sequence acts as a PTS for AGT is in 
some doubt due to the finding that mutation of the -KSKL 
sequence of firefly luciferase to -KKKL appears to abolish 
peroxisomal targeting ability in transfected monkey kidney 
cell cultures (Gould et al.,  1989).  Nevertheless, the likeli- 
hood of the amino-terminal sequence of AGT being directly 
involved in peroxisomal targeting remains small. No amino- 
terminal PTSs have been reported to date, although it has 
been suggested (Arakawa et al.,  1987)  that an amino-ter- 
,~o;  ~  Rg=~ 8. Putative pemxisomal 
DGFGELCHRYK  .......  KKKL--COOH  AGT  targeting sequences of AGT. 
IIII  I  I I[  Comparison with  firefly IU- 
NQRGELCVRGP  .......  KSKL  --  COOH  Luciferase  l  1  ciferase. The sequence around 
388  550  the glycine residue at position 
170 (which is replaced by an 
arginine by the Gt~A mutation) shows some homology to an in- 
ternal sequence of firefly peroxisomal luciferase. The COOH-ter- 
minal sequences of these proteins are also similar, although the ly- 
sine residue third from the end appears to prevent this sequence 
acting as a peroxisomal targeting sequence (Gould et al., 1987). 
minal region  of rat peroxisomal 3-oxoacyl CoA thiolase 
which is absent from the mitochondrial isozyme may play an 
indirect role in peroxisomal  targeting by masking the adja- 
cent region of the protein, which is the putative MTS of the 
mitochondrial isozyme. 
A second possible mechanism by which acquisition of an 
amino-terminal MTS could disrupt peroxisomal targeting is 
via a hierarchical system of expression of the two targeting 
sequences, whereby the amino-terminal MTS is recruited by 
mitochondria before synthesis and folding of the internal or 
carboxy-terminal PTS. This would require rapid and efficient 
commitment to the mitochondrial import pathway to achieve 
the low level of pAGT seen in patients with mAGT, which 
appears to be at odds with the rather low steady-state levels 
of mAGT in these patients. For instance, patients A-C, each 
of whom express a single allele carrying the C]s4T mutation 
and appear to have "~50%  normal levels  of AGT mRNA 
(Takada et al.,  1990;  Purdue, P. E., unpublished observa- 
tions), have only 5.6-8.7 % normal enzyme levels and much 
reduced levels of immunoreactive protein. There is no rea- 
son to expect that the protein is unstable in the mitochon- 
drion, since it appears to retain its enzymatic activity (Dan- 
pure et al.,  1989). 
It is perhaps more reasonable to expect that the adventi- 
tious MTS formed by the proline to leucine conversion at res- 
idue 11 is a rather inefficient  targeting sequence which, when 
present together with an intact functional PTS,  will only 
reroute a small proportion of  the AGT to the mitochondrion. 
In this case, the loss of AGT peroxisomal targeting and/or 
retention activity might be expected to lead to an increase 
in the functional expression of the MTS. Whether this is the 
situation for the mutant AGT in patients with mAGT remains 
to be resolved, but there is some preliminary evidence that 
the Gt~A mutation is also directly involved in the rerouting 
of AGT. This is based upon the observation that there is a 
dual localization of AGT in the liver of an individual who 
is  homozygous for  the  C]54T and  Am2G mutations,  but 
lacking the G~,oA  mutation. The proportion of AGT rerouted 
to the mitochondrion in this individual is small (<10%), but 
significant, and this indicates that at least two mutations are 
required to give rise to the pattern of AGT sorting found in 
PH1 patients with mAGT. This suggests that the Ct54T (and/ 
or AH42G) mutation(s) is sufficient for the generation of an 
inefficient MTS, but that the additional presence of the G~A 
mutation is required to effect functional expression of this 
targeting  sequence  to  the  near  exclusion of peroxisomal 
import. 
The  most  likely hypothesis to  explain this  is  that the 
G63oA mutation affects peroxisomal targeting and/or reten- 
tion of AGT. Small et al. (1988) have reported that internal 
sequences are involved in the peroxisomal targeting of Acyl- 
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this is the only report to date of an internal PTS, a number 
of glycosomal enzymes of the Trypanosomatidae  are appar- 
ently targeted by internal  highly charged sequences which 
are expressed as topogenic signals on the surface of the mol- 
ecule (Opperdoes, 1988). It has been suggested that a similar 
mechanism  could be involved in targeting  of peroxisomal 
proteins (Opperdoes, 1988), a hypothesis that is not incom- 
patible with the identification  of COOH-terminal  PTSs in 
firefly  luciferase  and  several  other  peroxisomal  proteins 
(Gould et al.,  1987,  1988,  1989;  Miyazawa et al.,  1989), 
since a number of peroxisomal proteins (possibly including 
human AGT) do not have an SKL or equivalent variant near 
the COOH-terminus (Borst,  1986,  1989). 
The glycine to arginine change induced by the Gt~A mu- 
tation  lies  within  a  stretch  of 44  amino  acids  (residues 
133-176; Fig. 1 c) that are identical to the corresponding re- 
gion of rat AGT, whose dual localization in peroxisomes and 
mitochondria is consistent with the presence of an internal 
or carboxy-terminal PTS (Takada et al.,  1990; Oda et al., 
1987). This degree of conservation suggests that this region 
of the protein is crucial to the functional expression of pAGT 
and that the maintenance of activity and/or import would be 
fairly intolerant  to mutations within this region.  Although 
the AGT activities in the mitochondrial variant PHI patients 
are fairly low (<30 % normal) they are all roughly propor- 
tional to the level of immunoreactive protein,  which indi- 
cates that the pathological  effect of the G6~A mutation  is 
probably not a result of impaired enzymatic activity of the 
residual mitochondrial  protein. 
It is our opinion that these observations suggest a role for 
the sequence around residue 170 in the peroxisomal target- 
ing of AGT. It is interesting to note that this sequence, which 
is reasonably highly charged, shows partial homology to an 
internal sequence of firefly luciferase (Fig. 8) (de Wet et al., 
1987). The identification of this sequence, and that around 
residue 11, as candidate peroxisomal and mitochondrial tar- 
geting sequences, respectively, will be of great help in the 
design of in vitro mutagenesis experiments to define these 
sorting signals in detail. 
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